HIV-1 RNA viral suppression is comparable between tenofovir alafenamide (TAF)/emtricitabine (FTC) + dolutegravir (DTG), tenofovir disoproxil fumarate (TDF)/FTC + DTG, and TDF/FTC/efavirenz (EFV) regimens, according to updated results of the ADVANCE trial.
In the treatment of patients with type 2 diabetes mellitus, both glucagon-like peptide-1 receptor agonists (GLP1-RAs) and sodium-dependent glucose cotransporter-2 inhibitors (SGLT2-Is) help lower blood pressure, improve glucose control without inducing weight gain, and confer cardio- and renoprotection, as shown in a study.
A comprehensive meta-analysis of 13 prospective studies evaluating eight* fructose-containing foods revealed that not all fructose-containing sugar sources are adversely associated with metabolic syndrome (MetS).
Use of metformin leads to improved oncological outcomes in diabetic patients with nonmuscke invasive bladder cancer treated with intravesical Bacille Calmette-Guerin (BCG), according to a Singapore study.
A quantitative analysis of patient perspective during the first years after a successful weight reduction has identified four solid barriers to weight loss maintenance, namely mental distress, binge eating, hedonic hunger, and demoralization.
Switching to a single-tablet triple-drug combination comprising bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) is well tolerated while continuing to provide virologic suppression through to 48 weeks in elderly people (aged ≥65 years) living with HIV (PLWH), shows a pooled analysis presented at the AIDS 2020 virtual conference.
Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.
The substitution of isoleucine to leucine at amino acid 97 (I97L) in the core region of the hepatitis B virus (HBV) seems to reduce its potency, decreasing the efficiency of both infection and the synthesis of the virus’ covalently closed circular (ccc) DNA, reports a new study presented at The Liver Meeting Digital Experience by the American Association for the Study of Liver Diseases (AASLD 2020).